TFX Teleflex Incorporated

Teleflex Focuses on Advancing Respiratory Care at AARC Congress 2016

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, will showcase its broad portfolio of products for Respiratory Care at the American Association for Respiratory Care (AARC) Congress 2016, October 15-18, in San Antonio, TX. During the event, Teleflex will highlight solutions for Mechanical Ventilation, High Flow Nasal Cannula Therapy, as well as solutions for Arterial Access.

At the Congress, Teleflex will be highlighting the Hudson RCI® Comfort Flo® Plus Cannula, the Hudson RCI® Neptune® Heated Humidifier with ConchaSmartTM Technology and recent portfolio additions from Maxtec®, a leader in oxygen analysis and delivery products for more than 15 years. With these Maxtec additions, Teleflex offers respiratory care professionals a turn-key solution for heated high flow nasal cannula therapy (HFNCT), a new standard of care for patients with acute hypoxemic respiratory failure. HFNCT has been shown to improve survival rates in these patients compared to standard Oxygen Masks or Non-Invasive Ventilation.1

“Teleflex is committed to providing advanced solutions to meet the evolving needs of the respiratory care professional,” said James Ferguson, President of Teleflex, Respiratory Division. “We are proud to be an AARC corporate partner and we are dedicated to enhancing the quality of patients’ lives by improving outcomes through clinical education and technology advancements for respiratory care.”

As respiratory therapists’ scope of practice continues to expand and the placement of arterial catheters is becoming more commonplace in this field, Teleflex will also be highlighting Arrow® Arterial Catheters. The Arrow® Brand leads the market2 with a comprehensive product line of arterial catheters and CDC compliant kits. On Friday, October 14, there will be a preconference educational session titled “Arterial Fundamentals: Ultrasound Guided Arterial Catheter Insertion.” The four-hour simulation course will review best practices for arterial catheter insertion and knowledge of prevention, recognition and management of insertion-related complications from arterial catheters. Teleflex is proud to support the expanded role of the respiratory therapist to include arterial catheter insertion.

Teleflex is honored to invite AARC Congress attendees to stop by Teleflex booth #623 in support of the American Respiratory Care Foundation (ARCF). Teleflex will be donating up to $30,000 to ARCF for AARC Congress attendee in-booth participation, further demonstrating our commitment to connecting clinicians with education in a way that helps improve patient outcomes and advances respiratory care throughout the world.

Learn more at teleflex.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Comfort Flo, ConchaSmart, Deknatel, Hudson RCI, LMA, Neptune, Pilling, Rusch, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2016 Teleflex Incorporated. All rights reserved. MC-002723

References:

  1. Frat JP, Thille AW, Mercat A, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. The New England Journal of Medicine 2015: DOI: 10.1056/NEJMoa1503326
  2. IMS Data 2015.

EN
12/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved ...

First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents WAYNE, Pa., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the enrollment of the first patient in the DUBSTENT DIABETES trial. The randomized, investigator-initiated clinical study will evaluate a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes mellitus. The ...

 PRESS RELEASE

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcar...

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at . About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the ...

 PRESS RELEASE

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a...

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced Barrigel™ rectal spacer is now available for pur...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Teleflex Inc: 5 directors

Five Directors at Teleflex Inc bought 5,500 shares at between 114.750USD and 115.860USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch